Pharnext SCA
OTC:PNEXF
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
999 999.9999
999 999.9999
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pharnext SCA
Pharnext SCA
Total Current Liabilities
Pharnext SCA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SCA
OTC:PNEXF
|
Total Current Liabilities
€10.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€102.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Current Liabilities
€38.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€36.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
10%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€48.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Current Liabilities
€52.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
Pharnext SCA
Glance View
Pharnext SCA, a biopharmaceutical innovator, stands as a pioneer in the world of "pleotherapy," a unique approach that repurposes existing drugs to simultaneously target multiple disease pathways. Founded in 2007 by renowned scientists, the company has developed a proprietary drug discovery platform known as PLEOTHERAPY™. This platform ingeniously combines network pharmacology with advanced algorithms, allowing Pharnext to identify optimal combinations of existing molecules. Such combinations, termed "pleodrugs," are designed to tackle complex neurological diseases for which there are currently few effective treatments. By leveraging already approved compounds, Pharnext significantly streamlines the path to clinical development, reducing both time and cost—a critical advantage in the pharmaceutical sector. Monetary gains for Pharnext primarily arise from developing and partnering these novel pleodrugs. By focusing on rare neurological conditions, such as Charcot-Marie-Tooth disease type 1A (CMT1A), Pharnext positions itself in niche markets with unmet medical needs and limited competition. Their lead candidate, PXT3003 for CMT1A, exemplifies this strategy, promising a new therapeutic avenue for patients while potentially establishing a new revenue stream upon commercialization. Moreover, Pharnext often collaborates with other pharmaceutical firms to both share the financial burden of drug development and enhance market penetration, thus diversifying and amplifying its income sources. Through its innovative model and strategic partnerships, Pharnext seeks to carve out a distinct and profitable niche within the biopharmaceutical landscape.
See Also
What is Pharnext SCA's Total Current Liabilities?
Total Current Liabilities
10.9m
EUR
Based on the financial report for Jun 30, 2023, Pharnext SCA's Total Current Liabilities amounts to 10.9m EUR.
What is Pharnext SCA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
3%
Over the last year, the Total Current Liabilities growth was -55%. The average annual Total Current Liabilities growth rates for Pharnext SCA have been 5% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
